Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States

International Journal of Antimicrobial Agents

Volumn 12, Issue 4, 1999, Pages 341-347

  Osato, Michael S ^a   Reddy, Rita ^a   Graham, David Y ^a,b  

^a Section of Infectious Diseases   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Clarithromycin; Helicobacter pylori; Resistance

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DATA BASE; FEMALE; GASTRITIS; HELICOBACTER PYLORI; HOSPITAL INFECTION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PEPTIC ULCER; PRIORITY JOURNAL; UNITED STATES;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOSPITALS, URBAN; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; UNITED STATES;

EID: 0033179196     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00079-5     Document Type: Article

References (61)

1. Graham D.Y., de Boer W.A., Tytgat G.N. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am. J. Gastroenterol. 91:1996;1072-1076.
2. Graham D.Y., Lew G.M., Malaty H.M., Evans D.G., Evans D.J. Jr, Klein P.D., Alpert L.C., Genta R.M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 102:1992;493-496.
3. Graham D.Y. Clarithromycin for treatment of Helicobacter pylori infections. Eur. J. Gastroenterol. Hepatol. 7(Suppl 1):1995;S55-S58.
4. van der Hulst R.W.M., Keller J.J., Raws E.A., Tytgat G.N.J. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter. 1:1996;3-19.
5. Yousfi M.M., El-Zimaity H.M.T., Al-Assi M.T., Cole R.A., Genta R.M., Graham D.Y. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 9:1995;209-212.
6. Ling T.K.W., Cheng A.F.B., Sung J.J.Y., Yiu P.Y.L., Chung S.S.C. An increase in Helicobacter pylori strains resistant to metronidazole: A five year study. Helicobacter. 1:1996;57-61.
7. Lopez-Brea M., Domingo D., Sanchez I., Alarcon T. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain. J. Antimicrob. Chemother. 40:1997;279-281.
8. Morton D, Bardham KD. A six-year assessment of tinidazole, metronidazole, clarithromycin, tetracycline and amoxicillin resistance in Helicobacter pylori clinical isolates: A rising tide of antibiotic resistance? Gastroenterology 1998; A235.
9. van der Wouden E.J., van Zwet A.A., Vosmaer G.D., Oom J.A., de Jong A., Kleibeuker J.H. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg. Infect. Dis. 3:1997;385-389.
10. Adamek R.J., Suerbaum S., Pfafenbach B., Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin - influence on treatment outcome. Am. J. Gastroenterol. 93:1998;386-389.
11. Anonymous, 1992. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 11:777-81.
12. Banatvala N., Davies G.R., Abdi Y., Clements L., Rampton D.S., Hardie J.M., Feldman R.A. High prevalence of Helicobacter pylori metronidazole resistance in immigrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut. 35:1994;1562-1566.
13. Buckley M.J., Xia H.X., Hyde D.M., Keane C.T., O'Morain C.A. Metronidazole resistance reduces the efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig. Dis. Sci. 42:1997;2111-2115.
14. Ching C.K., Leung K.P., Yung R.W., Lam S.K., Wong B.C., Lai K.C., Lai C.L. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut. 38:1996;675-678.
15. Lerang F., Moum B., Haug J.B., Tolas P., Breder O., Aubert E., Hoie O., Soberg T., Flaaten B., Farup P., Berge T. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am. J. Gastroenterol. 92:1997;248-253.
16. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment. Pharmacol. Ther. 11(Suppl 1):1997;43-53.
17. Midolo P.D., Lambert J.R., Turnidge J. Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy. J. Gastroenterol. Hepatol. 11:1996;290-292.
18. Rautelin H., Seppala K., Renkonen O.V., Vaino U., Kosunen T.U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob. Agents. Chemother. 36:1992;163-166.
19. van Zwet A.A., de Boer W.A., Schneeberger P.M., Weel J., Jansz A.R., Thijs J.L. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;861-864.
20. Fock K.M. Peptic ulcer disease in the 1990's: an Asian perspective. J. Gastroenterol. Hepatol. 12:1997;S23-28.
21. Hachem C.Y., Clarridge J.E., Evans D.G., Graham D.Y. Comparison of agar based media for primary isolation of Helicobacter pylori. J. Clin. Pathol. 48:1995;714-716.
22. Anonymous, 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed, NCCLS Approved Standard. M7-A4.
23. Dore M.P., Sepulveda A.R., Mura I., Realdi G., Osato M.S., Graham D.Y. Explanation for variability of omeprazole-amoxicillin therapy? Tolerance of H. pylori to amoxicillin. Gastroenterology. 112:1997;A105.
24. Adeyemi E.O., Fadlalla H., al-Homsi M., Nnalue N.A., Goodwin S., Boehme D., Sim A.J. Clinicopathological assessment of gastric biopsy samples of patients with Helicobacter pylori infection - metronidazole resistance and compliance problems in the United Arab Emirates. Ital. J. Gastroenterol. 24:1992;436-439.
25. Bell G.D., Powell K., Burridge S.M., Pallecaros A., Jones P.H., Gant P.W., Harrison G., Trowell J.E. Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol. Therap. 1992:1992;427-435.
26. Buckley M.J., Xia H.X., Hyde D.M., Keane C.T., O'Morain C.A. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig. Dis. Sci. 42:1997;2111-2115.
27. der Hulst R.W., van der Ende A., Homan A., Roorda P., Dankert J., Tytgat G.N. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut. 42:1998;166-169.
28. Hulten K., Jaup B., Stenquist B., Engstrand L. Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance. Helicobacter. 2:1997;188-193.
29. Lerang F., Moum B., Raghildstveit E., Sandvei P.K., Tolas P., Whist J.E., Henriksen M., Haug J.B., Berge T. Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance. Am. J. Gastroenterol. 93:1998;212-216.
30. Megraud F., Occhialini A., Doermann H.P. Resistance of Helicobacter pylori to macrolides and nitroimidazole compounds. The current situation. J. Physiol. Pharmacol. 48(Suppl 4):1997;25-38.
31. Veldhuyzen an Zaten S., Hunt R.H., Cockeram A., Schep G., Malatjalian D., Sidorov J., Matisko A., Jewell D. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance. Am. J. Gastroenterol. 93:1998;2-3.
32. Xia H.X., Daw M.A., Beattie S., Keane C.T., O'Morain C.A. Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients. Ir. J. Med. Sci. 162:1993;91-94.
33. Edwards D.I. Nitroimidazole drugs - action and resistance mechanisms. I. mechanisms of action. J. Antimicrob. Chemother. 31:1993;9-20.
34. Lockerby D.L., Rabin H.R., Laishley E.J. Role of the phosphoroclastic reaction of Clostridium pasteurianum in the reduction of metronidazole. Antimicrob. Agents. Chemother. 27:1985;863-867.
35. Muller M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery. 93:1983;165-171.
36. Lacey S.L., Moss S.F., Taylor G.W. Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori. J. Antimicrob. Chemother. 32:1993;393-400.
37. Moore R.A., Beckthold B., Bryan L.E. Metronidazole uptake in Helicobacter pylori. Can. J. Microbiol. 41:1995;746-749.
38. Smith M.A., Edwards D.L. Redox potential and oxygen concentration as factors in the susceptibility of Helicobacter pylori to nitroheterocyclic drugs. J. Antimicrob. Chemother. 35:1995;751-764.
39. Smith M.A., Edwards D.L. The influence of microaerophilia and anaerobiosis on metronidazole uptake in Helicobacter pylori. J. Antimicrob. Chemother. 36:1995;453-461.
40. Cederbrant G., Kahlmeter G., Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 29:1992;115-120.
41. Hoffman P.S., Goodwin A., Johnsen J., Magee K., Veldhuyzen van Zanten S.J. Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J. Bacteriol. 178:1996;4822-4829.
42. Jorgensen M.A., Manos J., Mendz G.L., Hazell S.L. The mode of action of metronidazole in Helicobacter pylori: futile cycling or reduction? J. Antimicrob. Chemother. 41:1998;67-75.
43. Smith M.A., Edwards D.I. Oxygen scavenging, NADH oxidase and metronidazole resistance in Helicobacter pylori. J. Antimicrob. Chemother. 39:1997;347-353.
44. Goodwin A., Kersulyte D., Sisson G., Veldhuyzen van Zanten S.J., Berg D.E., Hoffman P.S. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28:1998;383-393.
45. Kwon D.H., Versalovic J., Perng C.L., Woo J.S., Graham D.Y., Go M.F., El-Zaatari F.A.K., Kaihovaara P., Salaspuro M. The role of Helicobacter pylori flavodoxin encoding gene (fldA) in metronidazole resistance. Gastroenterology. 114:1998;A796.
46. Kwon DH, Osato MS, Graham DY, El-Zaatari FAK. Transcriptional repression of multiple genes involved in Helicobacter pylori metronidazole resistance. Submitted to Antimicrob Ag Chemother.
47. Hulten K., Gibreel A., Skild O., Engstrand L. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob. Agents Chemother. 41:1997;2550-2553.
48. Stone G.G., Shortridge D., Versalovic J., Beyer J., Flamm R.K., Graham D.Y., Ghoneim A.T., Tanaka S.K. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob. Agents. Chemother. 41:1997;712-714.
49. Szczebara F., Dhaenens L., Vincent P., Husson M.O. Evaluation of rapid molecular methods for detection of clarithromycin resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 16:1997;162-164.
50. Taylor D.E., Ge Z., Purych D., Lot T., Hiratsuka K. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. 41:1997;2621-2628.
51. Versalovic J., Osato M.S., Spakovsky K., Dore M.-P., Reddy R., Stone G.G., Shortridge D., Flamm R.K., Tanaka S.K., Graham D.Y. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J. Antimicrob. Chemother. 40:1997;283-286.
52. Versalovic J., Shortridge D., Kibler K., Griffy M.V., Beyer J., Flamm R.T., Tanaka S.K., Graham D.Y., Go M.F. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 40:1996;477-480.
53. Weissfeld A, Haber M, Rose P, Kidd S, Seipman N. Geographical distribution in the United States of primary resistance to clarithromycin and metronidazole in patients infected with Helicobacter pylori. Gastroenterology 1997;A328.
54. Peits U, Nusch A, Tillenburg B, Starke T, Stolte M, Borsch G, Labenz J. Impact of treatment duration and metronidazole resistance on H. pylori (Hp) cure with omeprazole, metronidazole and clarithromycin. Gastroenterology 1997;A255.
55. Schluter U, Bermands AT, Biemond I, Witte AMC, Gotz JM, Lamers CBHW, van Boven CPA, Veenendaal RA. Significance of routine corpus biopsies and incidence of antimicrobial resistance (metronidazole, clarithromycin) in Helicobacter pylori infection. Gastroenterology 1997;A282.
56. Ito S, Azuma T, Ito Y, Suto H, Yamazaki Y, Sato R, Ohtaki Y, Hirai M, Kuriyama M, Kohli Y, Keida Y. The prevalence of the drug resistance in Helicobacter pylori and the effects of the resistance on the eradication therapy in Japan. Gastroenterology 1997;A222.
57. Kubota T, Sato R, Murakami K, Kimoto M, Fujioka T, Nasu M. An increase in antibiotic-resistant Helicobacter pylori strains after new triple therapy. Gastroenterology 1998;A190.
58. Takahashi S., Itoh T., Ninomiya H., Hoshiya S., Watanabe K., Tokunaga K., Tanaka A., Nakamura N., Masubuchi N., Shingaki M., Saito S. Evolution of Helicobacter pylori antibiotic resistance in Japan. Gastroenterology. 1998:1985;A303.
59. Xia HX, Keane CT, O'Morain CA. A 5-year survey of metronidazole and clarithromycin resistance in clinical isolates of Helicobacter pylori. Gut 1996;39 (Suppl. 2):1A:09.
60. Dehesa M, Larisch J, Di Silvio M, Dibildox M, Alaguer I, Gonzalez G, Ramires-Barba EJ, Torres J, Comparison of three seven day pantoprazole (Panto) based Helicobacter pylori (Hp) eradication schemes in a Mexican population with highly metronidazole (Met) resistant Hp strains. Gastroenterology 1998;A99.
61. Fedorak R, Archambault A, Flamm R, Osato M, Stamler D. Antimicrobial susceptibility of H. pylori in Canada to three key antibiotics: Metronidazole, clarithromycin and amoxicillin. Gastroenterology 1997;A115.